Articles On Actinogen Medical (ASX:ACW)

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 has had its worst day in roughly a month with a 1.29 percentage dip  The sectors were a shade of spilt claret, with Utilities and Real Estate leading losses Standout small caps: BCAL Diagnostics and American West Metals   Loca...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

Actinogen Medical's (ASX:ACW) chief medical officer, Dr Dana Hilt, has presented an academic poster to the Alzheimer’s Association International Conference in Amsterdam.

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsyc...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

ShareCafeIron ore surge not enough to lift the ASX: Aus shares close 0.16% lower by Peter Milios   Iron ore prices have reached a seven-month high due to increased demand expectations from China after its reopening following a Covid-19 surg...

ShareCafeASX down 0.15% at noon despite spike in US markets by Peter Milios   The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Actinogen Medical (ACW) receives approval from the USA FDA to proceed with its six-month, phase 2b, placebo-controlled clinical trial of Xanamem Under the planned trial, Actinogen will enrol 330 patients with mild Alzheimer’s Disease and...

Actinogen Medical is a biotech with a potentially "gazillion" dollar opportunity in its Alzheimer's drug. By Tim Boreham ASX code: ACW Market cap: $215.7 million Share price: 12 cents Shares on issue: 1,797,393,817 Chief executive officer:...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeWebinar Recap – ACW, EEG & KNB Catch up on the full webinar presentations from Actinogen Medical (ASX: ACW), Empire Energy (ASX: EEG) & Koonenberry Gold (ASX: KNB) Webinar Recap – ACW, EEG & KNBCompany News

ShareCafeActinogen Medical (ASX:ACW) – Webinar Presentation Dr. Steven Gourlay – Managing Director & CEO – Actinogen Medical is a biotechnology company developing an innovative treatment for cognitive impairment associated with neurolo...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

ASX 200 ends 1.4% lower Small caps slide 0.4% Strike strikes and I don’t know why    The ASX 200 and the Emerging Companies (XEC) index fell 1.4% and 0.4% respectively on Monday. US stocks were no help at all after collapsing sharply on F...

ASX 200 abandoned play after decent start Small cap index gives back 1.3% Dundas shares jump on ultramafic magic   Local markets disappointed me today. So rather than start on an ill note, let’s take a quick spin around the Asia-Pacific...

Clinical Dementia Rating Scale – Sum of Boxes effect of 0.6 to 0.8 points observed in patients with elevated pTau biomarker with once daily, 10 mg, oral therapy SYDNEY, Oct. 10, 2022 /PRNewswire/ – Actinogen Medical Limited (ASX: ACW) today...

Actinogen Medical (ACW) sees new “positive” data from its phase 2A Alzheimer Disease (AD) biomarker studyThe study tested the company’s drug, Xanamem, on 72 patients across the US, UK and Australia with previously identified mild ADResults...

ASX slides early and long on Monday Small cap index crashes -2.3% Besra Gold (ASX:BEZ) just tripled its own sense of self   We’re all in the same boat on Monday, floating aimlessly about the big blue of the Pacific amidst inflation and it...

The share market started the week with a sharp loss as investors booked profits from last week’s rally ahead of US inflation data and a new US earnings season. The S&P/ASX 200 slumped 95 points or 1.4 per cent to a second-straight de...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and dropped deep into the red. At the time of writing, the benchmark index is down 1.5% to 6,662.6 points. Four ASX shares that are not letting that h...

The S&P/ASX 200 Index (ASX: XJO) is down 1.69% today, but one ASX biotech share is bucking the trend. The Actinogen Medical Ltd (ASX: ACW) share price soared 56% in early trade before pulling back. The company’s share price is up 30%...

ShareCafeRough start to the week, all sectors in the red: ASX down 1.4 per cent at noon by Lauren Hayes   It was always going to be a dismal start to the trading week following Wall Street tumbling on Friday, after a stronger-than-expected...

ShareCafeStocks of the Hour: HLX, ACW, GAL                    Helix Resources (ASX:HLX) provided an update this morning on the ongoing copper exploration drilling at its Canbelego Joint Venture Project located in the Cobar region of N...

10 Oct 2022 - A snapshot of the stocks on the move featuring Helix Resources (ASX:HLX), Actinogen Medical (ASX:ACW) and Galileo Mining (ASX:GAL).

Australian shares fell for a second day as US equity futures retreated ahead of inflation data and the start of a new earnings season later this week. The S&P/ASX 200 declined 105 points or 1.55 per cent to 6658 by mid-session. The i...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Benchmark finishes up after fierce struggle for buoyancy Absolutely no one shocked to learn Star’s worn out its welcome in QLD A solid arvo by little league miners was a well-timed boost It’s been a somewhat indecisive day for Aussie mark...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Actinogen Medical (ASX:ACW) has provided further information on the timing and design of its upcoming biomarker study in patients with mild Alzheimer’s disease.

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Actinogen Medical (ACW) finalises the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD) The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and dep...